Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2011 | 40 | 4 | 605-617
Tytuł artykułu

Conveying quality and value in emerging industries: Star scientists and the role of signals in biotechnology

Treść / Zawartość
Abstrakt, słowa kluczowe
Źródło
Twórcy
Bibliografia
Dodatkowe informacje
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
This paper addresses the role that scientific status plays in initial public offerings of technology focused firms. The paper builds on the literature of the sociology of science as well as the work of Spence (1974) and Podolny (1993) and argues that the presence of a Nobel laureate affiliated with a firm making an IPO provides a signal of firm quality to potential investors. Moreover, and building on the work of Podolny and Scott Morton (1999) and Stuart et al. (1999) we hypothesize that the importance of status diminishes as other measures of firm quality become available. We test our hypothesis for two periods of initial public offerings in biotechnology. We document that there is a clear difference in “maturity” of the firms across the two windows on a number of metrics. Consistent with our hypothesis that Nobel laureates play an important role as a non-financial signal of firm quality, we find that first-window firms with a Nobel laureate affiliate realize greater IPO proceeds in the amount of $24 million. In the second window the amount of money raised is not significantly different between Nobel and non-Nobel firms. This finding is consistent with the signaling literature that argues that the importance of a signal is inversely related to the availability of cogent information on firm quality. Consistent with this view, we also find a change between the two windows in the importance of other non-financial metrics used to convey value. Our research is one of the first to examine the dynamic nature of signals. Because we are unable to distinguish the extent to which the reduction in uncertainty at the firm level is correlated with the reduction of uncertainty at the industry level, the question remains as to the extent to which the diminished importance of signals in our second period is due to a change in market uncertainty versus a change in firm uncertainty.
Czasopismo
Research Policy , ISSN 00487333
Rocznik
Tom
40
Numer
4
Strony
605-617
Opis fizyczny
Twórcy
  • College of Management, Georgia Institute of Technology, 800 West Peachtree Street, NW, Atlanta, GA 30308-0520, United States , matt.higgins@mgt.gatech.edu
  • Department of Economics, Georgia State University & NBER, United States
  • College of Management, Georgia Institute of Technology, United States
Bibliografia
  • 1. Adegbesan, T.& Higgins, M.J., "The intra-alliance division of value created through collaboration", Strategic Management Journal, vol. 32, 2, 2011, p.187-211
  • 2. Aggarwal, R., "Stabilization activities by underwriters after initial public offerings", Journal of Finance, vol. 55, 2000, p.1075-1103
  • 3. Audretsch, D.& Stephan, P., "Company–scientist locational links: the case of biotechnology", American Economic Review, vol. 86, 1996, p.641-652
  • 4. Beatty, R.& Ritter, J., "Investment banking, reputation, and the underpricing of initial public offerings", Journal of Financial Economics, vol. 15, 1986, p.213-232
  • 5. Barry, C& Muscarella, C.& Peavy, J.& Vetsuypens, M., "The role of venture capital in the creation of public companies: evidence from the going-public process", Journal of Financial Economics, vol. 27, 1990, p.447-471
  • 6. Booth, J.& Smith, R., "Capital raising, underwriting and the certification process", Journal of Financial Economics, vol. 15, 1986, p.261-281
  • 7. Brau, J.& Fawcett, S., "Initial public offerings: an analysis of theory and practice", Journal of Finance, 2006, p.399-435
  • 8. Burrill, G.S., "Biotech 89: Into the Marketplace", 1988
  • 9. Burton, D.& Sorenson, J.& Beckman, C., "Coming from good stocks", Research in Sociology of Organizations, vol. 19, 2002, p.239-262
  • 10. Campbell, T.& Kracaw, W., "Information production, market signaling, and the theory of financial intermediation", Journal of Finance, vol. 35, 1980, p.863-882
  • 11. Carter, R& Dark, F.& Singh, A., "Underwriter reputation, initial returns and the long-run performance of IPO stocks", Journal of Finance, vol. 53, 1, 1998, p.285-311
  • 12. Carter, R.& Manaster, S., "Initial pubic offerings and underwriter reputation", Journal of Finance, vol. 45, 1990, p.1045-1068
  • 13. Chan, Y., "On the positive role of financial intermediation in allocation of venture capital in a market with imperfect information", Journal of Finance, vol. 38, 5, 1983, p.1543-1568
  • 14. Chemmanur, T., "The pricing of initial public offerings: a dynamic model with information production", Journal of Finance, vol. 48, 1993, p.285-304
  • 15. Chemmanur, T.& Fulghieri, P., "Investment bank reputation, information production, and financial intermediation", Journal of Finance, vol. 49, 1, 1994, p.57-79
  • 16. Deeds, D.L& Mang, P.& Frandsen, M., "The influence of firms’ and industries’ legitimacy on the flow of capital into high-technology ventures", Strategic Organization, vol. 2, 1, 2004, p.9-34
  • 17. Elfenbein, D., "Publications patents and the market for university inventions", Journal of Economic Behavior & Organization, vol. 63, 4, 2007
  • 18. Fombrun, C.& Shanley, M., "What's in a name? Reputation building and corporate strategy", Academy of Management Journal, vol. 33, 1990, p.233-258
  • 19. Frank, R.H., "Choosing the Right Pond: Human Behavior and the Quest for Status", 1985
  • 20. Graham, S., Higgins, M.J., 2010. The impact of patenting on new product introductions in the pharmaceutical industry. Unpublished working paper, Georgia Institute of Technology, College of Management.
  • 21. Grinblatt, M.& Hwang, C., "Signaling and the price of new issues", Journal of Finance, vol. 47, 1989, p.393-420
  • 22. Guo, R.J.& Lev, B.I.& Zhou, N., "The valuation of biotech IPOs", Journal of Accounting, Auditing & Finance, vol. 20, 4, 2005, p.188-244
  • 23. Hall, B.& Jaffe, A.& Trajtenberg, M., "Market value and patent citations", RAND Journal of Economics, vol. 36, 2005, p.16-38
  • 24. Higgins, M.J., "The allocation of control rights in pharmaceutical alliances", Journal of Corporate Finance, vol. 13, 2007, p.58-75
  • 25. Higgins, M.J., "Introduction to finance and the valuation of early stage technologies", Libecap, G. (Eds.), Advances in the Study of Entrepreneurship, Innovation, and Economic Growth, vol. vol. 18, 2007
  • 26. Higgins, M.& Gulati, R., "Getting off to a good start: the effects of upper echelon affiliations on underwriter prestige", Organization Science, vol. 14, 3, 2003, p.244-263
  • 27. Hsu, D., Ziedonis, R., 2007. Patents as quality signals for entrepreneurial ventures. Unpublished working paper, Stephen M. Ross School of Business, University of Michigan.
  • 28. Kenney, M., "Biotechnology: The University––Industrial Complex", 1986
  • 29. Leland, H.& Pyle, D., "Information asymmetries, financial structure, and financial intermediation", Journal of Finance, vol. 32, 1977, p.371-387
  • 30. Lerner, J., "Venture capitalists and the decision to go public", Journal of Financial Economics, vol. 35, 1994, p.293-316
  • 31. Lerner, J.& Shane, H.& Tsai, A., "Do equity financing cycles matter?: Evidence from biotechnology alliances", Journal of Financial Economics, vol. 67, 2003, p.411-446
  • 32. Loughran, T.& Ritter, J., "The new issues puzzle", Journal of Finance, vol. 58, 1995, p.723-752
  • 33. McLaughlin, R.& Safieddine, A.& Vasudevan, G., "Investment banker reputation and the performance of seasoned equity issuers", Financial Management, 2000, p.96-110
  • 34. Meggison, W.& Weisss, K., "Venture capitalist certification in initial public offerings", Journal of Finance, vol. 46, 3, 1991, p.879-901
  • 35. Merton, R.K., "The Matthew Effect in science", Science, vol. 159, 1968, p.56-63
  • 36. Metrick, A., "Venture Capital and the Finance of Innovation", 2006
  • 37. Nicholson, S.& Danzon, P.& McCullough, J., "Biotech-pharmaceutical alliances as a signal of asset and firm quality", Journal of Business, vol. 78, 2005, p.1433-1464
  • 38. Pisano, G., "Can science be a business? Lessons from biotech", Harvard Business Review (October), 2006, p.114-125
  • 39. Podolny, J., "A status-based model of market competition", American Journal of Sociology, vol. 98, 4, 1993, p.829-872
  • 40. Podolny, J.& Scott Morton, F., "Social status, entry and predation: the case of British shipping cartels 1879–1929", Journal of Industrial Economics, vol. 47, 1, 1999, p.41-67
  • 41. Powell, W.W, "Interorganizational collaboration in the biotechnology industry", Journal of Institutional and Theoretical Economics, vol. 152, 1, 1996, p.197-216
  • 42. Ritter, J.R.& Welch, I., "A review of IPO activity, pricing, and allocations", Journal of Financial Economics, 2002, p.1795-1828
  • 43. Rothaermel, F.T& Hess, A., "Building dynamic capabilities: innovation driven by individual, firm, and network-level effects", Organization Science, vol. 18, 6, 2007, p.898-921
  • 44. Sine, W.& Shane, S.& Di Gregorio, D., "The halo effect and technology licensing: the influence of institutional prestige on the licensing of university inventions", Management Science, vol. 49, 4, 2003, p.478-496
  • 45. Spence, M., "Market Signaling", 1974
  • 46. Stuart, T.& Hoang, H.& Hybels, R., "Interorganizational endorsement and the performance of entrepreneurial ventures", Administrative Science Quarterly, vol. 44, 1999, p.315-349
  • 47. Titman, S.& Trueman, B., "Information quality and the valuation of new issues", Journal of Accounting and Economics, vol. 8, 1986, p.159-172
  • 48. Werth, B., "The Billion-Dollar Molecule: One Company's Quest for the Perfect Drug", 1994
  • 49. Zucker, L.G.& Darby, M.R., "Individual action and the demand for institutions: star scientists and institutional transformation", American Behavioral Scientist, vol. 40, 1997, p.502-513
  • 50. Zucker, L.G.& Darby, M.R.& Armstrong, J., "Commercializing knowledge: university science, knowledge capture and firm performance in biotechnology", Management Science, vol. 48, 2002, p.138-153
  • 51. Zucker, L.G.& Darby, M.R.& Brewer, M.B., "Intellectual capital and the birth of U.S. biotechnology enterprises", American Economic Review, vol. 88, 1998, p.290-306
Kolekcja
Elsevier
Identyfikator YADDA
bwmeta1.element.elsevier-3aad3de3-eb54-3c5c-b9c7-ac9b2f32702a
Identyfikatory
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.